Brainstorm Cell Therapeutics Inc. (BCLI) Social Stream
BRAINSTORM CELL THERAPEUTICS INC (BCLI) Price Targets From Analysts
Use the tables below to see what analysts covering BRAINSTORM CELL THERAPEUTICS INC think about its future price and what recommendations they have for investors and traders.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-08-06 | 2 | $12 | $11 | $11.5 | $1.61 | 614.29% |
| 2021-11-17 | 1 | $12 | $11 | $11.5 | $1.61 | 614.29% |
| 2021-11-26 | 1 | $11 | $8 | $9.5 | $1.61 | 490.06% |
| 2021-12-13 | 2 | $14 | $8 | $11 | $1.61 | 583.23% |
| 2022-05-24 | 1 | $14 | $8 | $11 | $1.61 | 583.23% |
| 2022-08-17 | 1 | $21 | $8 | $14.5 | $1.61 | 800.62% |
| 2022-11-18 | 1 | $9 | $5 | $7 | $1.61 | 334.78% |
Price Target Last Issued November 18, 2022
The Trend in the Analyst Price Target
Over the past 30 months, BCLI's average price target has gone down $6.5.
BCLI reports an average of 284.1% for its upside potential over the past 33 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2022-04-04 | 1 | 14 | 8 | 11.0 | 3.42 | 221.64% |
| 2022-05-24 | 1 | 14 | 8 | 11.0 | 2.89 | 280.62% |
| 2022-08-17 | 1 | 21 | 8 | 14.5 | 3.85 | 276.62% |
| 2022-11-18 | 1 | 9 | 5 | 7.0 | 1.53 | 357.52% |
BCLI Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1 | 1 | 0 | 0 | 0 | 0 | 1 |
The Trend in the Broker Recommendations
Over the past 25 months, BCLI's average broker recommendation rating improved by 0.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- To contextualize these metrics, consider that out of all US stocks, BRAINSTORM CELL THERAPEUTICS INC's number of analysts covering the stock is higher than 6.6% of them.
- In terms of how BRAINSTORM CELL THERAPEUTICS INC fares relative to all US stocks, note that its upside potential (average analyst target price relative to current price) is higher than 651.3% of that group.
- BCLI has a greater average analyst price target than 139.21% of Healthcare stocks.
- To contextualize these metrics, consider that out of Pharmaceutical Products stocks, BRAINSTORM CELL THERAPEUTICS INC's variance in analysts' estimates is lower than -111.62% of them.
In the Pharmaceutical Products industry, CRIS, AGEN, and PTE are the three stocks most similar to BRAINSTORM CELL THERAPEUTICS INC regarding the price target and analyst recommendation information presented here.
View All Top Stocks by Price Target
Is BCLI a Buy, Hold or Sell? See the POWR Ratings now!